SKB BIO-B (06990) surged more than 5% intraday, and as of press time, it was up 4.46% to HK$431.2, with a trading volume of HK$106 million.

Recently, Merck initiated a rare financing move for sacituzumab govitecan (sac-TMT), securing $700 million from Blackstone to fund the global development of this product by 2026. Merck retains decision-making and control rights over the development, production, and commercialization of sac-TMT, exchanging future revenue rights for this financing.

Sac-TMT, a key ADC drug licensed by SKB BIO-B (06990) to Merck in 2022, has already drawn significant industry attention. The strategic financing highlights Merck's strong commitment to sac-TMT. According to Merck’s 2025 ASCO investor briefing, Phase III clinical trial data for sac-TMT will be disclosed intensively between 2027 and 2029. These critical data releases will further validate sac-TMT's global market potential and solidify its core position in Merck’s oncology pipeline.

The collaboration with Merck reflects Blackstone’s deep confidence in sac-TMT’s potential, as it provides funding to accelerate its global development.